NeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
ROLLE, SWITZERLAND -- (Marketwired) -- 11/09/17 -- NeoGenomics Inc. (NASDAQ: NEO), a leading global specialty oncology testing laboratory, opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community. Rolle was chosen as NeoGenomics' European Headquarters because of the existing talent pool, favorable business environment, and proximity to leading academic institutions in Geneva and Lausanne.
The event kicked off with a ribbon-cutting ceremony and remarks by NeoGenomics' Chairman and CEO, Douglas VanOort, and a brief presentation of NeoGenomics' oncology testing services by Dr. Steven Brodie and Dr. Gina Wallar. There were personalized tours of the facility by NeoGenomics' leadership, finishing off with meetings with local government officials. The open house kicks off NeoGenomics' official plans to provide esoteric testing for the global oncology research community.
"NeoGenomics is absolutely delighted to open our first specialized oncology laboratory outside the United States here in Rolle," said Douglas VanOort. "The canton of Vaud is known for its growing life sciences industry, and we are very appreciative of the opportunity to join this vibrant community. We also appreciate the warm welcome from governmental officials here, and look forward to many years of growth for this new facility."
Mr. Philippe Leuba, Minister of Economic Affairs, Innovation and Sport, State of Vaud stated "The launch of NeoGenomics' activities in Rolle follows the announcement of the Incyte manufacturing plant in Yverdon-les-Bains yesterday. More than ever, our canton, and more generally the entire Health Valley of Western Switzerland, is profiling itself as a leading center of scientific and industrial expertise in Europe. The presence of more than 20,000 people active in the field of life sciences in the canton of Vaud offers a unique and privileged access to a pool of talents necessary for the development of companies and their innovations."
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
Image Available: http://www.marketwire.com/library/MwGo/2017/11/8/11G147639/Images/MultimediaAsset1-298797937.jpg
For further information, please contact:
NeoGenomics, Inc.
Steven C. Jones
Director of Investor Relations
(239) 325-2001
sjones@neogenomics.com
Source: NeoGenomics, Inc.
Released November 9, 2017
